Navigation Links
Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to Donepezil in Patients with Alzheimer's Disease
Date:4/15/2009

ation

Medivation and Pfizer have a global collaboration to develop and commercialize Dimebon for the treatment of Alzheimer's and Huntington's diseases. Under the terms of the agreement, the companies are working in partnership to bring Dimebon to market in the United States (U.S.). In addition, following FDA approval, Medivation will co-promote Dimebon to specialty physicians in the U.S. Pfizer has responsibility for development, regulatory and commercialization outside of the U.S.

For more information about Pfizer, visit www.Pfizer.com.

For more information about Medivation, visit www.Medivation.com

Forward-Looking Statements

PFIZER DISCLOSURE NOTICE: The information contained in this release is as of April 15. Pfizer assumes no obligation to update any forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about certain potential indications for Dimebon, including their potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development; decisions by regulatory authorities regarding whether and when to approve any new drug applications that may be filed for such indications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of any such indications; and competitive developments.

A further list and description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and in its reports on Form 10-Q and Form 8-K.

MEDIVATION DISCOSURE NOTIC
'/>"/>

SOURCE Pfizer Inc; Medivation, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
2. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
3. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
4. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
5. MannKind Addresses Pfizers Announcement Regarding Exubera
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
8. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
9. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
10. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
11. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... LOUISVILLE, Ky. , Jan. 15, 2014  Manufacturers, ... technologies must be able to protect their most ... (Logo: http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because ... Industry, it steadfastly remains one of the most ...
(Date:1/15/2014)... , Jan. 15, 2014 MultiCell Technologies, Inc. ... a U.S. provisional patent application concerning composition of matter, ... achieve targeted tumor cell death.  This ... noncoding double stranded RNA molecules (VSRNAs) which interfere with ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3
(Date:7/9/2014)... More scientific research into the metabolism of stromal support ... the metabolism of these cell types in the development ... diabetes, inflammatory conditions and cancer. That was the conclusion ... KU Leuven in the leading journal Nature . ... sort of wake-up call. The metabolism of cancer cells ...
(Date:7/9/2014)... injection drug users in Russia might contribute to ... study, conducted by researchers from Boston University Schools ... St. Petersburg Pavlov State University, sought to discover ... outcomes of a cohort of HIV-positive people with ... were arrested by police were more likely to ...
(Date:7/9/2014)... release is available in French . ... in 14 year old teens, including brain structure and function, ... accuracy who will go on to develop binge drinking within ... conscientiousness, and other variables such as life events and a ... binge drinking. Whether or not the child had had ...
(Date:7/9/2014)... and extinctions around the world have been linked ... new research from the National Institute for Mathematical ... ranavirus, may also contribute. , In a ... which causes severe hemorrhage of internal organs in ... wood frogs if they are exposed to the ...
(Date:7/9/2014)... National Institute of Allergy and Infectious Diseases (NIAID), ... launched an early-stage clinical trial of CRS3123, an ... difficile ( C. difficile ) infection. CRS3123 ... that inhibits C. difficile growth while sparing normal ... enroll up to 30 healthy men and women ...
Breaking Medicine News(10 mins):Health News:Wake-up call for more research into cell metabolism 2Health News:BU researchers relate arrests with HIV risk environment 2Health News:What drives a child to abuse alcohol? 2Health News:Study predicts ranavirus as potential new culprit in amphibian extinctions 2Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2
... among those who apply the chemicals, study shows , ... pesticides have double the normal risk of developing a ... (monoclonal gammopathy of undetermined significance) and characterized by an ... monitoring because it can lead to multiple myeloma, a ...
... of Facebook, Twitter coincides with 30% drop in hours spent ... American kids and their parents are now spending more hours ... eroding the amount of time families spend together. , That,s ... week that families interact as group has fallen by nearly ...
... Power Plate(R) North America (PPNA), the global ... trend in fitness and beauty to the greater Los ... studio opening this month for the summer in Brentwood, ... machines, "Power Plate(R) - The Experience" will provide group ...
... stay up at night worrying whether they are going to develop ... and middle age is a lifetime away. As ... Feinberg School of Medicine have found that young adults (18 to ... a treadmill test -- are two to three times more likely ...
... scientists are among a multinational collaborative group to have ... European Union. The research will focus on ... common to all solid tumours. Hypoxia causes a ... resistant to radiotherapy and most forms of chemotherapy; as ...
... June 18 George Dahlman, senior vice president of ... testified today before the U.S. Senate Subcommittee on Defense ... cancer research program at the Department of Defense (DoD). ... determined that several blood cancers, including chronic lymphocytic leukemia ...
Cached Medicine News:Health News:Pesticides Linked to Blood Disorder 2Health News:Surging Internet Use Cutting Into Family Time 2Health News:Surging Internet Use Cutting Into Family Time 3Health News:Power Plate(R) Opens Cutting-Edge Studio in L.A. 2Health News:Aerobically unfit young adults on road to diabetes in middle age 2Health News:$16.8 million study will breathe new life into cancer battle 2Health News:The Leukemia & Lymphoma Society Calls for Blood Cancer Research Program at the Department of Defense 2
The generously sized STERILE VIEW Monk Hood from DePuy provides splash protection in the chin and neck areas from body fluids and liquids. Shoulder cut outs and ties ensure a comfortable fit. This pr...
STERILE VIEW Barrier Sleeves combine superior protection against contaminants with unsurpassed comfort and the convenience of universal sizing....
... UltraFit PK System rede phines sharpness ... trephine program for penetrating keratoplasty. Advanced ... cutting edge to achieve the critical fit ... disposable and fully customized system enables surgeons ...
Digital Imaging for Optical Screening:,Diabetes, Glaucoma Macular Degeneration, and other retinal disease....
Medicine Products: